Copyright
©The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. May 21, 2016; 22(19): 4638-4650
Published online May 21, 2016. doi: 10.3748/wjg.v22.i19.4638
Published online May 21, 2016. doi: 10.3748/wjg.v22.i19.4638
Recent updates of precision therapy for gastric cancer: Towards optimal tailored management
Moon Kyung Joo, Jong-Jae Park, Division of Gastroenterology, Department of Internal Medicine, Korea University College of Medicine Guro Hospital, Seoul 08308, South Korea
Hoon Jai Chun, Division of Gastroenterology and Hepatology, Department of Internal Medicine, Institute of Digestive Disease and Nutrition, Korea University College of Medicine, Seoul 02841, South Korea
Author contributions: Joo MK wrote the paper; Park JJ and Chun HJ revised the manuscript for critical intellectual contents.
Conflict-of-interest statement: None of the authors have potential conflicts (financial, professional, or personal) that are relevant to this publication.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Hoon Jai Chun, MD, PhD, AGAF, Division of Gastroenterology and Hepatology, Department of Internal Medicine, Institute of Digestive Disease and Nutrition, Korea University College of Medicine, 126-1, Anam-dong 5 ga, Seongbuk-gu, Seoul 02841, South Korea. drchunhj@chol.com
Telephone: +82-2-9206555 Fax: + 82-2-9531943
Received: January 27, 2016
Peer-review started: January 11, 2016
First decision: March 21, 2016
Revised: April 1, 2016
Accepted: April 20, 2016
Article in press: April 20, 2016
Published online: May 21, 2016
Processing time: 111 Days and 2.8 Hours
Peer-review started: January 11, 2016
First decision: March 21, 2016
Revised: April 1, 2016
Accepted: April 20, 2016
Article in press: April 20, 2016
Published online: May 21, 2016
Processing time: 111 Days and 2.8 Hours
Core Tip
Core tip: Among various cellular signaling pathways, hepatocyte growth factor/c-MET, phosphoinositide 3-kinase/Akt/mammalian target of rapamycin and janus kinase 2/signal transducer and activator of transcription 3 pathways are reportedly important in gastric carcinogenesis and metastasis. Aberrations of immune checkpoints have been vigorously investigated. However, clinical results of their target agents have not always matched the theoretical expectations of efficacy. In this review, we summarize the biologic impacts of the aforementioned signaling pathways, and their recent clinical outcomes including those of multiple kinase inhibitors in gastric cancer.